Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of α2-adrenoceptors in normal and medial forebrain bundle lesioned rats

Brain Research

Volumn 1324, Issue , 2010, Pages 64-74

  Wang, Yong ^a   Zhang, Qiao Jun ^b   Liu, Jian ^a   Ali, Umar ^a   Gui, Zhen Hua ^a   Hui, Yan Ping ^b   Wang, Tao ^a   Chen, Li ^a   Li, Qiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b the Second Affiliated Hospital   (China)

Author keywords

2 adrenoceptor; Extracellular recording; Locus coeruleus; Medial prefrontal cortex; Parkinson's disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; OXIDOPAMINE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; LOCUS CERULEUS; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT;

ACTION POTENTIALS; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; LOCUS COERULEUS; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROTOXINS; NOREPINEPHRINE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PREFRONTAL CORTEX; PYRAMIDAL CELLS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; YOHIMBINE;

RATTUS;

EID: 77949912219     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.02.009     Document Type: Article

References (59)

1. 2A-adrenergic receptor-like immunoreactivity. Brain Res. 650 (1994) 181-204
2. Arnsten A. Catecholamine regulation of the prefrontal cortex. J. Psychopharmacol. 11 (1997) 151-162
3. 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230 (1985) 1273-1276
4. Barth A., Vizi E., Zelles T., and Lendvai B. Alpha2-adrenergic receptors modify dendritic spike generation via HCN channels in the prefrontal cortex. J. Neurophysiol. 99 (2008) 394-401
5. Bastian J., and Nguyenkim J. Dendritic modulation of burst-like firing in sensory neurons. J. Neurophysiol. 85 (2001) 10-22
6. Belujon P., Bezard E., Taupignon A., Bioulac B., and Benazzouz A. Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J. Neurosci. 27 (2007) 9595-9606
7. Bernardi G., Cherubini E., Marciani M.G., Mercuri N., and Stanzione P. Responses of intracellularly recorded cortical neurons to the iontophoretic application of dopamine. Brain Res. 245 (1982) 267-274
8. Bosboom J., Stoffers D., and Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J. Neural Transm. 111 (2004) 1303-1315
9. Bunney B.S., and Aghajanian G.K. Dopamine and norepinephrine innervated cells in the rat prefrontal cortex: pharmacological differentiation using microiontophoretic techniques. Life Sci. 19 (1976) 1783-1789
10. Caillé S., Espejo E., Reneric J., Cador M., Koob G., and Stinus L. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. J. Pharmacol. Exp. Ther. 290 (1999) 881-892
11. Cash R., Ruberg M., Raisman R., and Agid Y. Adrenergic receptors in Parkinson's disease. Brain Res. 322 (1984) 269-275
12. Cocatre-Zilgien J., and Delcomyn F. Identification of bursts in spike trains. J. Neurosci. Methods 41 (1992) 19-30
13. Cummings J. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149 (1992) 443-454
14. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317
15. Devoto P., Flore G., Longu G., Pira L., and Gessa G. Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 50 (2003) 200-205
16. Devoto P., Flore G., Saba P., Castelli M., Piras A., Luesu W., Viaggi M., Ennas M., and Gessa G. 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. J. Neurosci. Res. 86 (2008) 1647-1658
17. 1-adrenoceptor binding in dorsal noradrenergic bundle-lesioned rats. Brain Res. 420 (1987) 152-156
18. Fulceri F., Biagioni F., Ferrucci M., Lazzeri G., Bartalucci A., Galli V., Ruggieri S., Paparelli A., and Fornai F. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res. 1135 (2007) 219-229
19. Fuster J.M. The Prefrontal Cortex: Anatomy, Physiology and Neuropsychology of the Frontal Lobe. 3rd ed. (1997), Lippincott-William & Wilkins, Philadelphia
20. Graeber M., Grasbon-Frodl E., Eitzen U., and Kösel S. Neurodegeneration and aging: role of the second genome. J. Neurosci. Res. 52 (1998) 1-6
21. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 326 (2006) 541-551
22. Kawahara H., Kawahara Y., and Westerink B. The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. Eur. J. Pharmacol. 418 (2001) 177-186
23. Lategan A., Marien M., and Colpaert F. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523 (1990) 134-138
24. Lategan A., Marien M., and Colpaert F. Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Life Sci. 50 (1992) 995-999
25. Lee C., Sauer H., and Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72 (1996) 641-653
26. Li B., Mao Z., Wang M., and Mei Z. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21 (1999) 601-610
27. MacDonald E., Kobilka B., and Scheinin M. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18 (1997) 211-219
28. Mantz J., Milla C., Glowinski J., and Thierry A.M. Differential effects of ascending neurons containing dopamine and noradrenaline in the control of spontaneous activity and of evoked responses in the rat prefrontal cortex. Neuroscience 27 (1988) 517-526
29. Millan M., Newman-Tancredi A., Audinot V., Cussac D., Lejeune F., Nicolas J., Cogé F., Galizzi J., Boutin J., Rivet J., Dekeyne A., and Gobert A. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35 (2000) 79-95
30. Miller E., and Cohen J. An integrative theory of prefrontal cortex function. Annu. Rev. Neurosci. 24 (2001) 167-202
31. Oades R.D., and Halliday G.M. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res. Rev. 12 (1987) 117-165
32. Ordway G. Effect of noradrenergic lesions on subtypes of alpha 2-adrenoceptors in rat brain. J. Neurochem. 64 (1995) 1118-1126
33. Oswald A., Chacron M., Doiron B., Bastian J., and Maler L. Parallel processing of sensory input by bursts and isolated spikes. J. Neurosci. 24 (2004) 4351-4362
34. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 5th ed (2005), Academic Press, New York
35. Ramos B., and Arnsten A. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther. 113 (2007) 523-536
36. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
37. Ridderinkhof K., Ullsperger M., Crone E., and Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 306 (2004) 443-447
38. Riekkinen M., and Riekkinen P.J. Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease. J. Clin. Psychopharmacol. 19 (1999) 444-449
39. Rückert N., Bubser M., and Schmidt W. 6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats. J. Neural Transm. 104 (1997) 363-377
40. Santana N., Bortolozzi A., Serrats J., Mengod G., and Artigas F. Expression of serotonin-1A and serotonin-2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 14 (2004) 1100-1109
41. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275 (1983) 321-328
42. Schapira A. Progress in Parkinson's disease. Eur. J. Neurol. 15 (2008) 1
43. Suzuki Y., Jodo E., Takeuchi S., Niwa S., and Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 114 (2002) 769-779
44. Séguéla P., Watkins K.C., Geffard M., and Descarries L. Noradrenaline axon terminals in adult rat neocortex: an immunocytochemical analysis in serial thin sections. Neuroscience 35 (1990) 249-264
45. Thierry A.M., Mantz J., and Glowinski J. Influence of dopaminergic and noradrenergic afferents on their target cells in the rat medial prefrontal cortex. Adv. Neurol. 57 (1992) 545-554
46. Tseng K.Y., Mallet N., Toreson K., Le Moine C., Gonon F., and O'Donnell P. Excitatory response of prefrontal cortical fast-spiking interneurons to ventral tegmental area stimulation in vivo. Synapse 59 (2006) 412-417
47. Tseng K.Y., and O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 24 (2004) 5131-5139
48. van Veldhuizen M., Feenstra M., Heinsbroek R., and Boer G. In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br. J. Pharmacol. 109 (1993) 655-660
49. Vanderwolf C., and Baker G. The role of brain noradrenaline in cortical activation and behavior: a study of lesions of the locus coeruleus, medial thalamus and hippocampus-neocortex and of muscarinic blockade in the rat. Behav. Brain Res. 78 (1996) 225-234
50. Vilardaga J., Steinmeyer R., Harms G., and Lohse M. Molecular basis of inverse agonism in a G protein-coupled receptor. Nat. Chem. Biol. 1 (2005) 25-28
51. 2 receptors in the rat medial prefrontal cortex. Synapse 19 (1995) 112-120
52. 1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb. Cortex 11 (2001) 452-462
53. 2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 1045 (2005) 229-233
54. 1A receptor stimulation in the rat. Neuroscience 159 (2009) 850-861
55. Waterhouse B., Lin C., Burne R., and Woodward D. The distribution of neocortical projection neurons in the locus coeruleus. J. Comp. Neurol. 217 (1983) 418-431
56. Williams S., and Stuart G. Mechanisms and consequences of action potential burst firing in rat neocortical pyramidal neurons. J. Physiol. 521 (1999) 467-482
57. Winterer G., and Weinberger D.R. Cortical signal-to-noise ratio: insight into the pathophysiology and genetics of schizophrenia. Clin. Neurosci. Res. 3 (2003) 55-66
58. Zarow C., Lyness S.A., Mortimer J.A., and Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003) 337-341
59. Zweig R., Cardillo J., Cohen M., Giere S., and Hedreen J. The locus ceruleus and dementia in Parkinson's disease. Neurology 43 (1993) 986-991